BÜHLMANN is very proud to announce that the calprotectin determination in stool starting from January 1st 2012, has an official new position in the reimbursement list of the Swiss Ministry of Health, increasing even more the availability, and the acceptance within the laboratories and above all, for the patients and doctors, from the specialist to the General Practitioner. The position code for calprotectin analysis is: N 1224.10 and is reimbursed with 61 Swiss Francs.
This has been achieved through excellent collaborations and a hand in hand effort between the Swiss authorities, independent experts in the medical, the laboratory chemistry and immunology field, as well as BÜHLMANN Laboratories, as one driving force to increase acceptance of the most important and useful biomarker available for IBD diagnosis.
This great achievement is also a very important milestone for reimbursement efforts in countries that are still on the way to this development. BÜHLMANN is certainly going to be in the lead towards this goal worldwide.
Since 2007 BÜHLMANN is fully commited in improving the position of this invaluable diagnostic tool and is the market leader for calprotectin determinations with the monoclonal ELISA assay, as well as the rapid and quantitative Quantum Blue® Calprotectin lateral flow test.